



NEWS RELEASE

Cardiff Lexington Announces Opening of Tenth Nova Ortho and Spine Location in Port St. Lucie, Florida

12/18/2023

FT. LAUDERDALE, FL / ACCESSWIRE / December 18, 2023 / The new 1,645 square foot facility at 1822 SE Port Saint Lucie Boulevard is in a key population center, expanding on the Company's already robust network of locations throughout Florida. Dr. Kevin Fitzgerald, managing partner and physician provider for Nova Ortho and Spine, will oversee the Port St. Lucie location. Dr. Fitzgerald has over 20 years of experience in the medical profession in various roles including physician, respiratory therapist, and physician's assistant. Prior to Nova Ortho and Spine, he was the in-patient medical director for the top hospital system in the United States, managing three hospitals with a total patient capacity of over 550.

With the addition of the location in Port St. Lucie, Nova Ortho and Spine currently has ten locations strategically dispersed throughout Florida with room for significant geographic growth.

Alex Cunningham, CEO of Cardiff Lexington, commented, "We're pleased to be expanding our Nova Ortho and Spine footprint with the opening of our tenth location in Port St. Lucie. The opening of this new location expands our presence in the Florida market where there are more personal injury claims per capita than any other state in the U.S. This is a key next step in bringing our exceptional orthopedic care to more people across Florida and ultimately the southeast, and we look forward to serving the Port St. Lucie community."

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a holding company focused on locating, acquiring, and building middle market,

niche companies, primarily in the healthcare industry. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.

A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, PLLC, or Nova, which the Company acquired in May of 2021 and operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.

For more information on Cardiff Lexington Corporation, you may access the company's website at <https://cardifflexington.com/>

Forward-Looking Statements

This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management's beliefs, assumptions and expectations of the Company's future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The Company does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in "Risk Factors" included in our filings with the Securities and Exchange Commission.

CONTACT:

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations

cardifflexington@imsinvestorrelations.com

(203) 972-9200

SOURCE: Cardiff Lexington Corporation

View the original **press release** on **accesswire.com**